What is the official website of Hikma Pharmaceuticals ?

The official website of Hikma Pharmaceuticals is http://www.hikma.com.

What is Hikma Pharmaceuticals's cybersecurity risk score?

Hikma Pharmaceuticals has an AI-generated cybersecurity risk score of 767 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Hikma Pharmaceuticals experienced?

According to Rankiteo, Hikma Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Hikma Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Hikma Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Hikma Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Hikma Pharmaceuticals is not certified under SOC 2 Type 1.

Does Hikma Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Hikma Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Hikma Pharmaceuticals comply with GDPR ?

According to Rankiteo, Hikma Pharmaceuticals is not listed as GDPR compliant.

Does Hikma Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Hikma Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Hikma Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Hikma Pharmaceuticals is not compliant with HIPAA regulations.

Does Hikma Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Hikma Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Hikma Pharmaceuticals operate in ?

Hikma Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals employs approximately 10,252 people worldwide.

Does Hikma Pharmaceuticals own any subsidiaries ?

Hikma Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals's official LinkedIn profile has approximately 637,630 followers.

What is the NAICS classification code for Hikma Pharmaceuticals ?

Hikma Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Hikma Pharmaceuticals have a Crunchbase profile ?

Yes, Hikma Pharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/hikma-pharmaceuticals.

Does Hikma Pharmaceuticals have a LinkedIn profile ?

Yes, Hikma Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hikma-pharmaceuticals.

How many cybersecurity incidents has Hikma Pharmaceuticals experienced ?

As of June 14, 2026, Rankiteo reports that Hikma Pharmaceuticals has not experienced any cybersecurity incidents.

How many peer or competitor companies does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals has an estimated 5,686 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Hikma Pharmaceuticals

Boost Score +25 with badge (5 left)

767

/1000

Fair

792

/1000

Fair

Hikma Pharmaceuticals Vendor Cyber Rating & Cyber Score

hikma.com

cb in

Add Your Compliance Badge

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Hikma Pharmaceuticals A.I CyberSecurity Scoring

Scoring History

Hikma Pharmaceuticals

Hikma Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Hikma Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Hikma Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Hikma Pharmaceuticals Subsidiaries

Parent Company

Hikma Pharmaceuticals

Pharmaceutical Manufacturing

Website: http://www.hikma.com

Company Size: 5,001-10,000 employees

No subsidiary data available for this company.

Loading…

Hikma Pharmaceuticals Similar Companies

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Loading…

NEWS

Hikma Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 05, 2026 08:00 AM

How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge

Hikma Pharmaceuticals is back in focus after its fair value estimate was trimmed from £21.82 to £20.47. This shift has put fresh attention...

Read Article

February 26, 2026 08:00 AM

Hikma Pharma's gloomy outlook kicks shares to more than three-year low

British generic drugmaker Hikma Pharmaceuticals scrapped its medium-term targets as it forecast slower annual revenue growth and profit on...

Read Article

February 06, 2026 08:00 AM

What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)

The latest update on Hikma Pharmaceuticals focuses on the price target, with the modelled fair value held at 22.14 while core assumptions...

Read Article

January 08, 2026 08:00 AM

Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value

Hikma Pharmaceuticals' fair value estimate has been nudged down from £22.66 to £22.00 per share, a small adjustment that better reflects the...

Read Article

December 16, 2025 08:00 AM

The Character of the Corporation 2025: Navigating Tumultuous Times for Multinational Businesses

Directors Nina Henderson and John Zangardi on the key differences between serving on multinational and domestic boards.

Read Article

December 15, 2025 08:00 AM

How the Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Target Moves

Hikma Pharmaceuticals' latest valuation update points to a slightly lower fair value estimate of about $22.66 per share, even as analysts...

Read Article

November 28, 2025 08:00 AM

How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation

Hikma Pharmaceuticals' consensus analyst price target has seen a slight dip, moving from £23.55 to £23.36 per share.

Read Article

November 13, 2025 08:00 AM

Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates

Hikma Pharmaceuticals has recently seen its fair value estimate reduced from £25.40 to £23.55, as analysts update their assessments in light...

Read Article

September 19, 2025 07:00 AM

Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company

Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12175

SUMMARY

A vulnerability was detected in CodeAstro Student Attendance Management System 1.0. Impacted is an unknown function of the file /attendance-php/Admin/createStudents.php. Performing a manipulation of the argument admissionNumber results in sql injection. Remote exploitation of the attack is possible. The exploit is now public and may be used.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 4.7)

cvss2

Base Score: 5.8

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:P/A:P

cvss3

Base Score: 4.7

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.2

REFERENCES

CVE-2026-12174

SUMMARY

A security vulnerability has been detected in D-Link DCS-935L 1.10.01. This issue affects the function snprintf of the file /web/cgi-bin/greece/rhea of the component HTTP Handler. Such manipulation of the argument data leads to format string. The attack may be launched remotely. The exploit has been disclosed publicly and may be used.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-12183

SUMMARY

Nefteprodukttekhnika BUK TS-G Gas Station Automation System 2.9.1 through 2.10.2 on Linux contains an Improper Authentication vulnerability (CWE-287) in the system configuration module. The /php/ajax-login.php endpoint returns userid=1 (administrator) in response to any HTTP POST request that supplies arbitrary credentials (e.g., action=dologin&login=<any_value>&pwd=<any_value>), and subsequent privileged endpoints under /php/ajax-main.php and /modules/* do not validate a server-side session. A remote unauthenticated attacker can invoke any administrative action exposed by the configuration module, including reading and modifying user rules, fuel tank gauges, fuel dispensers, relays, cash registers, bank terminals, fuel cards, price and customer displays, cash collection, and pricing rules.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:L/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-6428

SUMMARY

SQL Injection in reports/catalogue_out.pl in Koha Community Koha through 22.11.37, 23.x, 24.x before 24.11.16, 25.05.x before 25.05.11, 25.11.x before 25.11.05, 26.05.x before 26.05.01, and 26.11.x before 26.11.00 allows an authenticated staff user with the Reports module flag to read arbitrary data from the Koha application database via the Filter URL parameter when the Criteria parameter matches /branchcode/. The vulnerable sink in sub calculate concatenates the unmodified Filter request parameter directly into a LIKE clause of the auxiliary $strsth2 statement and executes it via DBI without bound parameters: my $f = @$filters[0]; $f =~ s/\*/%/g; $strsth2 .= " AND $column LIKE '$f' "; This enables error-based SQL injection (e.g., via EXTRACTVALUE) and full read access to sensitive tables including borrowers (password hashes, 2FA secrets, PII), borrower_password_recovery, api_keys, and sessions. Proof of concept (error-based, single request): GET /cgi-bin/koha/reports/catalogue_out.pl?do_it=1&output=screen&Limit=10&Criteria=branchcode&Filter=x'+AND+EXTRACTVALUE(1,CONCAT(0x7e,VERSION(),0x7c,USER(),0x7c,DATABASE(),0x7e))--+- Cookie: CGISESSID=<LIBRARIAN_SESSION> The response body contains the DBI exception leaking the MariaDB version, database user, client IP, and database name, after which arbitrary data can be paged out using LIMIT n,1 / SUBSTRING(...). The vulnerable sink was introduced in commit 6bb77ae3e4 (2008-07-09); CVE-2015-4633 patched the same class in sibling files but did not generalise the fix to reports/catalogue_out.pl. Fixed in Koha 22.11.38, 24.11.16, 25.05.11, 25.11.05, 26.05.01, and 26.11.00 by replacing the raw concatenation with a parameterised placeholder.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 7.6)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:N/A:P

cvss3

Base Score: 7.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:L/A:L

cvss4

Base Score: 5.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:H/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:Y/R:X/V:C/RE:X/U:Amber

Impact Score

4.7

Exploitability

2.8

REFERENCES

CVE-2026-5513

SUMMARY

The Online Scheduling and Appointment Booking System – Bookly plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the 'bookly-customer-full-name' cookie in versions up to, and including, 27.2 due to insufficient input sanitization and output escaping. This makes it possible for unauthenticated attackers to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page. Exploitation requires 'Remember personal information in cookies' setting to be enabled (disabled by default).

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 7.2)

cvss3

Base Score: 7.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:L/I:L/A:N

Impact Score

2.7

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…